arrow_back Back to App

Supporting November as Complex Regional Pain Syndrome Awareness Month

The House of Representatives supports designating November as Complex Regional Pain Syndrome (CRPS/RSD) Awareness Month. This aims to increase public and medical understanding of this rare, debilitating chronic pain condition, which is crucial for accelerating research and improving early diagnosis. While this resolution does not create new law, it provides symbolic support to patients and highlights the need for better treatment pathways.
Key points
Official support for designating November to raise awareness about the rare and painful CRPS/RSD condition.
Recognition of the critical need to advance research, develop new treatments, and improve diagnostic methods for this poorly understood disorder.
Emphasis on utilizing regulatory pathways, like the Accelerated Approval Pathway, for developing drugs for rare diseases.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HRES_903
Sponsor: Rep. Tonko, Paul [D-NY-20]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing support for the designation of November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month".

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HRES_903.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What are the main provisions?

Key points include:

  • Official support for designating November to raise awareness about the rare and painful CRPS/RSD condition.
  • Recognition of the critical need to advance research, develop new treatments, and improve diagnostic methods for this poorly understood disorder.
  • Emphasis on utilizing regulatory pathways, like the Accelerated Approval Pathway, for developing drugs for rare diseases.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Tonko, Paul [D-NY-20].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health